An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer

Official Title

A Randomized, Multicentre, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer

Summary:

The primary purpose of this study is to determine whether Nivolumab will improve disease-free survival compared with placebo.

Trial Description

Primary Outcome:

  • Disease-Free Survival of adjuvant nivolumab in participants with resected esophageal cancer or gastroesophageal junction cancer who have received chemoradiotherapy followed by surgery
Secondary Outcome:
  • Overall Survival of adjuvant nivolumab in participants with resected esophageal cancer or gastroesophageal junction cancer who have received chemoradiotherapy followed by surgery
  • Overall survival rate

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society